Innovation in the Faculty of Medicine
In the News
LAB150 is a drug development collaboration between MaRS Innovation and Evotec AG developed to accelerate Toronto’s academic research into market-ready products. With a combined multi-million dollar financial commitment by MaRS Innovation and Evotec AG, this newly formed partnership accelerates the development and commercialization of your drug discovery research programs and technologies with award amounts of $75k to $400k. For more information and to submit an application to LAB150, visit: www.lab150.com
Development and production of human vaccines, both prophylactic and therapeutic, including vaccines for chronic infectious diseases. Interest list here.
The premier life science incubator empowering and enabling innovators to deliver life-enhancing health and wellness solutions to people around the globe.
New resources for U of T Inventors and Entrepreneurs!
The Innovations & Partnerships Office (IPO) is pleased to provide two new resources for faculty, researchers, and students interested in commercializing research or starting a company: The Inventor's Guide to Technology Transfer and the Start-Up Guide. These guides provide practical information on: When and how to disclose an invention; Protecting intellectual property; Navigating U of T policies and conflict of interest; Getting funding; and Bringing the technology to market. If you or your department have any questions or would like to host a workshop to learn more, contact firstname.lastname@example.org.
Health Innovation Hub (H2i)
H2i was established to create a culture and infrastructure that aligns, connects, serves and facilitates student driven translation of discoveries and ideas into problem-solving designs that impact positively on health matters. This mission of H2i is to enable, collaborate, educate, and facilitate student initiated commercialization of health matters.
H2i in the news:
- UofTMed Alumni: Our Foray into Health Care Entrepreneurship, in AI and Radiology
- CCAB Partners With ImmunoBiochem as it Launches New Co-Development Strategy to Advance Early-Stage Biotech Companies
- U of T to quicken pace of heart research commercialization with new entrepreneurhsip progam
- Industry experts are helping U of T health startups scale the 'brick wall' of regulatory approval
- Restorative Breast Cancer Solution Start-Up Wins the 2018 FACIT Pitch Competition
- Two H2I client companies – Xpan and 16 Bit – take top prizes at RBC Innovation & Entrepreneurship awards
Centre for Collaborative Drug Research
A multidisciplinary initiative bringing together the Faculty of Medicine, the Leslie Dan Faculty of Pharmacy and the Centre for Addiction and Mental Health, the CCDR is designed to spur networking, collaboration and innovation in drug research. The CCDR is actively involved in developing new models for collaboration and innovation with the pharmaceutical industry and other partners. The Centre’s initial areas of research focus include: New Targets in Neuroscience, Natural Products in Health & Disease, Pharmacogenomics & Drug Safety, and New Approaches to Anti-infective Therapy.
Centre for Commercialization of Regenerative Medicine
Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and bioengineers have come together to form CCRM. CCRM’s mission is to generate sustainable health and economic benefits through global collaboration in cell and gene therapy, and regenerative medicine.
CCAB translates early stage biologics into high-value assets and products. Partners can access a robust portfolio of validated antibodies and biologics, powered by the University of Toronto’s antibody discovery engine, the Toronto Recombinant Antibody Centre (TRAC). From discovery and development to validation and licensing, CCAB reduces the time, risk, and costs associated with bringing new antibodies to market.
TBEP is the University of Toronto’s component of the Ted Rogers Centre for Heart Research (TRCHR). Occupying the 14th floor of MaRS Discovery District’s West Tower, TBEP brings together eight faculty members and their students from U of T Dentistry, Engineering and Medicine to advance heart research, diagnostics, and regeneration using a comprehensive approach that includes systems and developmental biology, technology innovation and clinical translation.
Institute of Biomaterials & Biomedical Engineering
IBBME researchers collaborate across the disciplines of engineering, medicine and dentistry to develop innovative solutions for the most pressing health-care challenges in the world. Learn about their four research themes in biomedical and clinical engineering that are shaping the next frontiers in human health.